Skip to content

Prognosis of Patients With Acute Coronary Syndrome Complicated With Renal Insufficiency(PACS-RI)

Study on the Prognosis of Patients With Acute Coronary Syndrome Complicated With Renal Insufficiency: a Prospective, Multicenter, Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03044990
Acronym
PACS-RI
Enrollment
2014
Registered
2017-02-07
Start date
2017-01-31
Completion date
2020-03-01
Last updated
2020-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

Acute coronary syndrome, renal insufficiency, mortality

Brief summary

Several epidemiologic studies reported that patients with renal insufficiency might have increased cardiovascular disease-related mortality rates after Percutaneous coronary intervention (PCI) . The increased risk in this population may be related to the less use of standard guideline-based treatment and the resulting inability to perform PCI effectively. Recently, with the technology improvement and the progress in clinical trials, Chinese guidelines have made new recommendations about the patients with acute coronary syndrome(ACS) in different states of renal function. However, scant epidemiologic information exists on the prognosis of those patients, especially in Henan. And there is still some uncertainty whether those patients are using the latest guideline recommended treatment. This multicenter, prospective, observational study is aimed to evaluate the long prognosis in patients with acute coronary syndrome complicated with renal insufficiency, and to analysis its related factors that influence the outcomes.

Detailed description

1. Henan institute of cardiology epidemiology is responsible for design, data quality control and statistical analysis. 2. Data were collected using a uniformed Case Report Form(CRF) by trained staff at each hospital. 3. Sample size estimation: Based on retrospective observational cohort of ACS patients, 1-year mortality in normal renal function and renal disfunction were 2.8% and 7.9%, respectively. To achieve a precision of 15% with an α of 0.05, the loss ratio of following-up is 10%.The investigators would need a sample of 2000. 4. Statistical analysis plan: the investigators will report summary statistics for patient characteristics, renal function status, comorbidities, treatment strategies and outcomes. the investigators will also undertake the following prespecified subgroup analyses: age, sex, STE-ACS or NSTE-ACS, history of diabetes, history of hypertension, smoking and Syntax score. 5. Quality assurance plan 1)Diagnosis of ACS is according to the third universal definition.2)Before registry, a training program on study objectives, data collection, and ACS management is given to the primary investigator and related staff at each participating center.3)Henan institute of cardiology epidemiology will regularly monitored at least 10% of CRFs for accuracy against medical records. If the CRFs are not completed with 98% accuracy, all CRFs are considered unqualified and this staff will be retrained.4)Before entering into the computer, data is queried for invalid and illogical values by research staff in Henan institute of cardiology epidemiology. Participating centres who has the high error rate of data, and no change in 6 months shall be deemed abandoned automatically; participating centres who has the high quality of data will be issued a certificate to reward.5)Investigator meeting will be annually held to conclude the progress, solve existing problems and strengthen program training.

Interventions

None listed

Sponsors

Henan Institute of Cardiovascular Epidemiology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age≥18 years. 2. Patients with clinical evidence of acute coronary syndrome, including ST segment elevation myocardial infarction (STEMI), non ST segment elevation myocardial infarction (NSTEMI) and unstable angina. 3. Informed consent signed by patients or legal guardians.

Exclusion criteria

1. Non-atherosclerotic coronary heart disease 2. Organ failure other than heart failure and kidney failure 3. Considered not fit for the study due to other reasons, including but not restricted to : a. Severe infection; b. cachexia;c.maintenance hemodialysis.

Design outcomes

Primary

MeasureTime frameDescription
Major adverse cardiovascular and cerebrovascular events1 yearincluding all-caused death, nonfatal- myocardial infarction,and stroke

Secondary

MeasureTime frameDescription
Coronary revascularization6 month,1 year
Re-hospitalized6 month,1 year
Renal-Replaced therapyAt discharge(an average of 10 days),6 month,1 year
Major adverse cardiovascular and cerebrovascular eventsAt discharge(an average of 10 days),6 monthincluding all-caused death, nonfatal- myocardial infarction,and stroke
Cardiogenic shockAt discharge(an average of 10 days)
New arrhythmiaAt discharge(an average of 10 days)
Bleeding according to GUSTO bleeding grade(excluding hemorrhage stroke)At discharge(an average of 10 days),6 month,1 year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026